文献速递白血病造血干细胞移植与细胞治疗

抗CLL1 CAR-T细胞治疗儿童复发或难治性急性髓系白血病的特点:多中心疗效与安全性期中分析

Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.
PubMed 文献 · Leukemia · 2022-09-23

该1/2期临床试验纳入8例复发或难治性急性髓系白血病(R/R-AML)患儿,评估自体抗CLL1 CAR-T细胞免疫治疗的安全性与初步疗效。患者经淋巴清除预处理后接受单次CAR-T输注,发生1-2级细胞因子释放综合征(CRS),无致死性事件。4例达形态学无白血病状态(MLFS)且微小残留病(MRD)阴性,结果提示抗CLL1 CAR-T可作为耐受良好且有效的选择。

要点

  • 8例R/R-AML患儿接受单次自体抗CLL1 CAR-T输注,发生1-2级CRS,无致死性事件。
  • 4例达MLFS且MRD阴性,1例MLFS但MRD阳性,1例达CRi但MRD阳性。
  • 1例达部分缓解(PR),1例疾病稳定(SD)但CLL1阳性AML原始细胞清除。

核心结论

  • 结果提示抗CLL1 CAR-T细胞免疫治疗可考虑作为儿童R/R-AML耐受良好且有效的治疗选择。

研究设计与样本

  • 多中心1/2期临床试验,纳入8例复发或难治性急性髓系白血病(R/R-AML)患儿。
  • 患者经淋巴清除预处理后接受单次自体抗CLL1 CAR-T细胞输注。
  • 试验目的为评估抗CLL1 CAR-T细胞治疗的安全性与初步疗效。

主要发现

  • CAR-T治疗后患者发生1-2级细胞因子释放综合征(CRS),无致死性事件。
  • 8例中4例达形态学无白血病状态(MLFS)且微小残留病(MRD)阴性。
  • 1例达MLFS但MRD阳性,1例达完全缓解伴血细胞不完全恢复(CRi)但MRD阳性。
  • 1例达部分缓解(PR),1例为疾病稳定(SD)但CLL1阳性AML原始细胞清除。

临床怎么用

  • 作者认为抗CLL1 CAR-T细胞免疫治疗可考虑用于儿童R/R-AML的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

C-type lectin-like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia (AML) stem cells and AML blasts, which can be considered as AML-associated antigen. Anti-CLL1-based CAR-T cells exhibited effective tumor-killing capacity in vitro and in AML-bearing mouse model. In this report, eight children with relapsed or refractory AML (R/R-AML) were recruited for a phase 1/2 clinical trial of autologous anti-CLL1 CAR-T cell immunotherapy. The objectives of this clinical trial were to evaluate the safety and the preliminary efficacy of anti-CLL1 CAR-T cell treatment. Patients received one dose of autologous anti-CLL1 CAR-T cells after lymphodepletion conditioning. After CAR-T treatment, patients developed grade 1-2 cytokine release syndrome (CRS) but without any lethal events. 4 out of 8 patients achieved morphologic leukemia-free state (MLFS) and minimal residual disease (MRD) negativity, 1 patient with MLFS and MRD positivity, 1 patient achieved complete remission with incomplete hematologic recovery (CRi) but MRD positivity, 1 patient with partial remission (PR), and 1 patient remained at stable disease (SD) status but had CLL1-positive AML blast clearance. These results suggested that anti-CLL1-based CAR-T cell immunotherapy can be considered as a well-tolerated and effective option for treating children with R/R-AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhang H, Bu C, Peng Z, et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia. 2022. PMID: 36151140. doi:10.1038/s41375-022-01703-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。